FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3176332560> ?p ?o ?g. }

• W3176332560 endingPage "175883592110196" @default.
• W3176332560 startingPage "175883592110196" @default.
• W3176332560 abstract "Trastuzumab combined with cisplatin and fluoropyrimidines, either capecitabine or 5-fluorouracile (XP/FP), is the standard first-line treatment for advanced, HER2-positive, gastric cancer patients based on the ToGA trial. Despite the lack of phase III trials, many clinicians administer trastuzumab with alternative regimens. One meta-analysis suggests that substituting cisplatin for oxaliplatin might lead to greater efficacy and less toxicity.594 patients with HER2-positive gastroesophageal adenocarcinoma were recruited from the AGAMENON-SEOM registry. The objective was to evaluate the external validity of clinical trials with chemotherapy and trastuzumab.The regimens used in at least 5% of the patients were XP (27%), oxaliplatin and capecitabine (CAPOX) (26%), oxaliplatin and 5-fluorouracil (FOLFOX) (14%), FP (14%), triplet with anthracycline/docetaxel (7%), and carboplatin-FU (5%). Median exposure to trastuzumab was longer with FOLFOX (11.4 months, 95% CI, 9.1-21.0) versus ToGA regimens (7.5, 6.4-8.5), p < 0.001. Patients with HER2-IHC 3+ cancers had higher response rates than those with IHC 2+/FISH+, odds-ratio 1.97 (95% CI, 1.25-3.09). The results achieved with CAPOX-trastuzumab were comparable to those attained with ToGA regimens. FOLFOX-trastuzumab was superior to ToGA schemes in terms of overall survival (OS), with a greater magnitude of effect in IHC 2+/FISH+ tumors (HR 0.47, 0.24-0.92) compared with IHC 3+ (HR 0.69, 0.49-0.96), and in diffuse (HR 0.37, 0.20-0.69) versus intestinal-type tumors (HR 0.76, 0.54-1.06).We have updated the external validity of clinical trials with trastuzumab in first-line treatment of gastric cancer. Our data confirm the comparable outcomes of ToGA regimens and CAPOX-trastuzumab in clinical practice and point toward a possible benefit of FOLFOX-trastuzumab, contingent on the subtypes typically less sensitive to trastuzumab, to be confirmed in clinical trials." @default.
• W3176332560 created "2021-07-05" @default.
• W3176332560 creator A5000829593 @default.
• W3176332560 creator A5004298052 @default.
• W3176332560 creator A5011514688 @default.
• W3176332560 creator A5011885884 @default.
• W3176332560 creator A5013546375 @default.
• W3176332560 creator A5016903080 @default.
• W3176332560 creator A5017427348 @default.
• W3176332560 creator A5017491147 @default.
• W3176332560 creator A5017607510 @default.
• W3176332560 creator A5023101865 @default.
• W3176332560 creator A5023149954 @default.
• W3176332560 creator A5031206323 @default.
• W3176332560 creator A5031470622 @default.
• W3176332560 creator A5031976935 @default.
• W3176332560 creator A5036309156 @default.
• W3176332560 creator A5037797945 @default.
• W3176332560 creator A5037937204 @default.
• W3176332560 creator A5040105917 @default.
• W3176332560 creator A5043472954 @default.
• W3176332560 creator A5045108507 @default.
• W3176332560 creator A5045435529 @default.
• W3176332560 creator A5064158750 @default.
• W3176332560 creator A5069587784 @default.
• W3176332560 creator A5069925163 @default.
• W3176332560 creator A5072809476 @default.
• W3176332560 creator A5074014021 @default.
• W3176332560 creator A5074441562 @default.
• W3176332560 creator A5076826212 @default.
• W3176332560 creator A5080562953 @default.
• W3176332560 creator A5086519139 @default.
• W3176332560 creator A5087359007 @default.
• W3176332560 date "2021-01-01" @default.
• W3176332560 modified "2023-10-10" @default.
• W3176332560 title "External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry" @default.
• W3176332560 cites W1703551835 @default.
• W3176332560 cites W1901107170 @default.
• W3176332560 cites W2005399294 @default.
• W3176332560 cites W2053719118 @default.
• W3176332560 cites W2072311746 @default.
• W3176332560 cites W2082145086 @default.
• W3176332560 cites W2087202011 @default.
• W3176332560 cites W2095605190 @default.
• W3176332560 cites W2100439220 @default.
• W3176332560 cites W2125776201 @default.
• W3176332560 cites W2126547130 @default.
• W3176332560 cites W2151217508 @default.
• W3176332560 cites W2247129539 @default.
• W3176332560 cites W2252468824 @default.
• W3176332560 cites W2512765729 @default.
• W3176332560 cites W2519531282 @default.
• W3176332560 cites W2548107068 @default.
• W3176332560 cites W2563490717 @default.
• W3176332560 cites W2601301706 @default.
• W3176332560 cites W2604415595 @default.
• W3176332560 cites W2610601822 @default.
• W3176332560 cites W2740733300 @default.
• W3176332560 cites W2771516752 @default.
• W3176332560 cites W2793855478 @default.
• W3176332560 cites W2794787607 @default.
• W3176332560 cites W2900604868 @default.
• W3176332560 cites W2901467300 @default.
• W3176332560 cites W2914092341 @default.
• W3176332560 cites W2925979405 @default.
• W3176332560 cites W2965889803 @default.
• W3176332560 cites W2965993818 @default.
• W3176332560 cites W2970021394 @default.
• W3176332560 cites W2995643185 @default.
• W3176332560 cites W3046382541 @default.
• W3176332560 cites W3088573844 @default.
• W3176332560 cites W4211255759 @default.
• W3176332560 cites W4254687493 @default.
• W3176332560 doi "https://doi.org/10.1177/17588359211019672" @default.
• W3176332560 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8216357" @default.
• W3176332560 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34211587" @default.
• W3176332560 hasPublicationYear "2021" @default.
• W3176332560 type Work @default.
• W3176332560 sameAs 3176332560 @default.
• W3176332560 citedByCount "4" @default.
• W3176332560 countsByYear W31763325602022 @default.
• W3176332560 countsByYear W31763325602023 @default.
• W3176332560 crossrefType "journal-article" @default.
• W3176332560 hasAuthorship W3176332560A5000829593 @default.
• W3176332560 hasAuthorship W3176332560A5004298052 @default.
• W3176332560 hasAuthorship W3176332560A5011514688 @default.
• W3176332560 hasAuthorship W3176332560A5011885884 @default.
• W3176332560 hasAuthorship W3176332560A5013546375 @default.
• W3176332560 hasAuthorship W3176332560A5016903080 @default.
• W3176332560 hasAuthorship W3176332560A5017427348 @default.
• W3176332560 hasAuthorship W3176332560A5017491147 @default.
• W3176332560 hasAuthorship W3176332560A5017607510 @default.
• W3176332560 hasAuthorship W3176332560A5023101865 @default.
• W3176332560 hasAuthorship W3176332560A5023149954 @default.
• W3176332560 hasAuthorship W3176332560A5031206323 @default.
• W3176332560 hasAuthorship W3176332560A5031470622 @default.
• W3176332560 hasAuthorship W3176332560A5031976935 @default.
• W3176332560 hasAuthorship W3176332560A5036309156 @default.

• next